
Mohammad A Kamal

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8072740/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Nanotechnology-based approaches in anticancer research. International Journal of Nanomedicine, 2012, 7, 4391.	6.7	217
2	Status of Acetylcholinesterase and Butyrylcholinesterase in Alzheimer's Disease and Type 2 Diabetes Mellitus. CNS and Neurological Disorders - Drug Targets, 2014, 13, 1432-1439.	1.4	209
3	A Synopsis on the Role of Tyrosine Hydroxylase in Parkinson's Disease. CNS and Neurological Disorders - Drug Targets, 2012, 11, 395-409.	1.4	111
4	Determination of sugars in honey by liquid chromatography. Saudi Journal of Biological Sciences, 2011, 18, 17-21.	3.8	74
5	Kinetics of Human Serum Butyrylcholinesterase Inhibition by a Novel Experimental Alzheimer Therapeutic, Dihydrobenzodioxepine Cymserine. Neurochemical Research, 2008, 33, 745-753.	3.3	60
6	Kinetics of human acetylcholinesterase inhibition by the novel experimental alzheimer therapeutic agent, tolserine. Biochemical Pharmacology, 2000, 60, 561-570.	4.4	59
7	Alzheimer's disease and type 2 diabetes via chronic inflammatory mechanisms. Saudi Journal of Biological Sciences, 2015, 22, 4-13.	3.8	58
8	Tetrahydrofurobenzofuran cymserine, a potent butyrylcholinesterase inhibitor and experimental Alzheimer drug candidate, enzyme kinetic analysis. Journal of Neural Transmission, 2008, 115, 889-898.	2.8	57
9	Effects of extremely low frequency electromagnetic field (ELF-EMF) on catalase, cytochrome P450 and nitric oxide synthase in erythro-leukemic cells. Life Sciences, 2015, 121, 117-123.	4.3	44
10	Kinetics of Human Erythrocyte Acetylcholinesterase Inhibition by a Novel Derivative of Physostigmine: Phenserine. Biochemical and Biophysical Research Communications, 1998, 248, 180-185.	2.1	43
11	Kinetics of human serum butyrylcholinesterase and its inhibition by a novel experimental Alzheimer therapeutic, bisnorcymserine. Journal of Alzheimer's Disease, 2006, 10, 43-51.	2.6	40
12	Alzheimer's Disease And Type 2 Diabetes: Exploring The Association To Obesity And Tyrosine Hydroxylase. CNS and Neurological Disorders - Drug Targets, 2012, 11, 482-489.	1.4	39
13	Mitochondria as an Easy Target to Oxidative Stress Events in Parkinson's Disease. CNS and Neurological Disorders - Drug Targets, 2012, 11, 430-438.	1.4	38
14	An overview on the correlation of neurological disorders with cardiovascular disease. Saudi Journal of Biological Sciences, 2015, 22, 19-23.	3.8	36
15	Kinetic analysis of the inhibition of human butyrylcholinesterase with cymserine. Biochimica Et Biophysica Acta - General Subjects, 2006, 1760, 200-206.	2.4	35
16	Chinese herbal extracts (SK0506) as a potential candidate for the therapy of the metabolic syndrome. Clinical Science, 2011, 120, 297-305.	4.3	32
17	Kinetic analysis of the toxicological effect of tacrine (Cognex®) on human retinal acetylcholinesterase activity. Toxicology, 2000, 147, 33-39.	4.2	31
18	Linking Alzheimer's Disease and Type 2 Diabetes Mellitus via Aberrant Insulin Signaling and Inflammation. CNS and Neurological Disorders - Drug Targets, 2014, 13, 338-346.	1.4	24

Mohammad A Kamal

#	Article	IF	CITATIONS
19	C-Peptide and its Correlation to Parameters of Insulin Resistance in the Metabolic Syndrome. CNS and Neurological Disorders - Drug Targets, 2011, 10, 921-927.	1.4	21
20	Interaction of Human Brain Acetylcholinesterase with Cyclophosphamide: A Molecular Modeling and Docking Study. CNS and Neurological Disorders - Drug Targets, 2011, 10, 845-848.	1.4	15
21	Inhibition of Butyrylcholinesterase with Fluorobenzylcymserine, An Experimental Alzheimer's Drug Candidate: Validation of Enzoinformatics Results by Classical and Innovative Enzyme Kinetic Analyses. CNS and Neurological Disorders - Drug Targets, 2017, 16, 820-827.	1.4	15
22	Nanoneurotoxicity to Nanoneuroprotection Using Biological and Computational Approaches. Journal of Environmental Science and Health, Part C: Environmental Carcinogenesis and Ecotoxicology Reviews, 2013, 31, 256-284.	2.9	14
23	Sensitivity of bovine retinal acetylcholinesterase (E.C. 3.1.1.7) toward tacrine: Kinetic characterization. Journal of Biochemical and Molecular Toxicology, 1998, 12, 245-251.	3.0	12
24	Molecular Interaction of the Antineoplastic Drug, Methotrexate with Human Brain Acetylcholinesterase: A Docking Study. CNS and Neurological Disorders - Drug Targets, 2012, 11, 142-147.	1.4	12
25	Molecular Docking Study of Catecholamines and [4-(Propan-2-yl) Phenyl]Carbamic acid with Tyrosine Hydroxylase. CNS and Neurological Disorders - Drug Targets, 2012, 11, 463-468.	1.4	11
26	Kinetics for Camel (Camelus dromedarius) Retina Acetylcholinesterase Inhibition by Methotrexate In Vitro. The Japanese Journal of Pharmacology, 1996, 72, 49-55.	1.2	8
27	Multiple Approaches to Analyse the Data for Rat Brain Acetylcholinesterase Inhibition by Cyclophosphamide. Neurochemical Research, 2010, 35, 1501-1509.	3.3	8
28	In vitro inhibition of human erythrocyte acetylcholinesterase (EC3.1.1.7) by an antineoplastic drug methotrexate. Molecular and Cellular Biochemistry, 1996, 159, 47-53.	3.1	5
29	Evaluation of the Nature of Camel Retinal Acetylcholinesterase: Inhibition by Hexamethonium. Journal of Enzyme Inhibition and Medicinal Chemistry, 1997, 12, 303-311.	0.5	5
30	Human erythrocyte acetylcholinesterase inhibition by cis-diamminediaquaplatinum (II): a novel kinetic approach. Cancer Letters, 1999, 138, 115-119.	7.2	5
31	Specific Cholinesterase Inhibitors: A Potential Tool to Assist in Management of Alzheimer Disease. , 2014, , 366-386.		5
32	Kinetics of the inhibition of acetylcholinesterase in camel retina by cisplatin. Cancer Letters, 1998, 128, 79-86.	7.2	4
33	Exploring N ¹ -p-Fluorobenzyl-Cymserine as an Inhibitor of 5-Lipoxygenase as a Candidate for Type 2 Diabetes and Neurodegenerative Disorder Treatment. CNS and Neurological Disorders - Drug Targets, 2014, 13, 197-202.	1.4	3
34	Dual Substrate Model for Novel Approach Towards a Kinetic Study of Acetylcholinesterase Inhibition by Diazinon. Journal of Enzyme Inhibition and Medicinal Chemistry, 2000, 15, 201-213.	0.5	2
35	Dissociation Between the Potent β-Amyloid Protein Pathway Inhibition and Cholinergic Actions of the Alzheimer Drug Candidates Phenserine and Cymserine. , 2008, , 445-462.		2
36	Kinetic constants for the inhibition of camel retinal acetylcholinesterase by the carbamate insecticide lannate. , 1999, 13, 41-46.		1